Your browser doesn't support javascript.
loading
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study.
Yao, Yiwei; Wang, Yong; Du, Yingying; Jiang, Fengshou; Liang, Hui; Bi, Minghong; Xie, Hua; Peng, Wanren; Pan, Yueyin.
Afiliación
  • Yao Y; Department of Oncology Chemotherapy, The First Affiliated Hospital of USTC, Hefei 230001, Anhui Province, China.
  • Wang Y; Department of Oncology Chemotherapy, The First Affiliated Hospital of USTC, Hefei 230001, Anhui Province, China.
  • Du Y; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China.
  • Jiang F; Department of Oncology Chemotherapy, The First Affiliated Hospital of USTC, Hefei 230001, Anhui Province, China.
  • Liang H; Department of Radiology, Traditional Chinese Hospital of LuAn, Luan 237006, Anhui Province, China.
  • Bi M; Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China.
  • Xie H; Department of Oncology, Xuancheng People's Hospital, Xuancheng 242000, Anhui Province, China.
  • Peng W; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China.
  • Pan Y; Department of Oncology Chemotherapy, The First Affiliated Hospital of USTC, Hefei 230001, Anhui Province, China. Electronic address: panyueyin@ustc.edu.cn.
Int Immunopharmacol ; 125(Pt B): 111147, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37956490
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares / Antineoplásicos Límite: Humans Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares / Antineoplásicos Límite: Humans Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China